Seattle-based Cell Therapeutics says that interim data from a Phase II/III trial of pixantrone demonstrated fewer severe side effects than the standard care for non-Hodkin's lymphoma. Compared with a group of patients receiving doxorubicin, researchers say that both arms of the trial achieved similar efficacy results with complete or partial tumor response among virtually all patients.
"We are excited by these results demonstrating that pixantrone is living up to the promise of preventing the severe cardiac damage that accompanies the use of standard doxorubicin treatment while retaining the potent anti-lymphoma activity of this class of drug," said James A. Bianco, M.D., President and CEO of CTI. "Pending results from this and other studies, these findings could have major implications for treating patients with breast cancer, lymphoma, and leukemia, where debilitating cardiac damage from doxorubicin might be prevented."
- read the report for more information
Related Articles:
Cell Therapeutics spins off new protein tech company. Report
Cell Therapeutics inks deal for Xyotax. Report
Cell Therapeutics makes bid to buy DOR. Report
Cell Therapeutics pays $10.5M to settle kickback claims. Report